Treatment of mouse liver slices with cholestatic hepatotoxicants results in down-regulation of Fxr and its target genes

BMC Medical Genomics

Volumn 6, Issue 1, 2013, Pages

  Szalowska, Ewa ^a   Stoopen, Geert ^a   Groot, Maria J ^a   Hendriksen, Peter Jm ^a   Peijnenburg, Ad Acm ^a  

^a WAGENINGEN UNIVERSITY   (Netherlands)

Author keywords

Alternatives for animal testing; Biomarkers; Cholestasis; Fxr (Nr1h4); Precision cut liver slices; Transcriptome

Indexed keywords

BILE ACID; CHLORPROMAZINE; CYCLOSPORIN A; FARNESOID X RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TRANSCRIPTOME; TRIACYLGLYCEROL;

ABCG5 GENE; ABCG8 GENE; ANIMAL TISSUE; ARTICLE; BAAT GENE; BILE ACID LIVER LEVEL; BILE ACID METABOLISM; CELL STRUCTURE; CHOLESTASIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DISEASE MARKER; DNA HYBRIDIZATION; DNA MICROARRAY; DOWN REGULATION; DRUG SCREENING; ENDOPLASMIC RETICULUM STRESS; ENERGY METABOLISM; EX VIVO STUDY; EXTRACELLULAR MATRIX; GENE EXPRESSION PROFILING; GENE TARGETING; GENOME; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INCUBATION TIME; INFLAMMATION; KLF15 GENE; LIVER; LIVER BIOPSY; LIVER CELL; LIVER LEVEL; LIVER NECROSIS; LIVER SLICE; LIVER TOXICITY; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STEATOSIS; TOXICITY TESTING; TRIACYLGLYCEROL LIVER LEVEL; UPREGULATION;

ANIMALIA;

ANIMALS; BIOLOGICAL MARKERS; CHLORPROMAZINE; CHOLESTASIS; CYCLOSPORINE; CYTOTOXINS; DOWN-REGULATION; GENE EXPRESSION PROFILING; HUMANS; LIVER; MALE; MICE; MICE, INBRED C57BL; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SIGNAL TRANSDUCTION;

EID: 84885096746     PISSN: None     EISSN: 17558794     Source Type: Journal    
DOI: 10.1186/1755-8794-6-39     Document Type: Article

References (58)

1. Drug-induced cholestasis. Velayudham LS, Farrell GC, Expert Opin Drug Saf 2003 2 3 287 304 10.1517/14740338.2.3.287 12904107
2. Role of bile acids and bile acid receptors in metabolic regulation. Lefebvre P, Cariou B, Lien F, Kuipers F, Staels B, Physiol Rev 2009 89 1 147 191 10.1152/physrev.00010.2008 19126757
3. Impact of different long-term maintenance immunosuppressive therapy strategies on patients' outcome after heart transplantation. Dandel M, Lehmkuhl HB, Knosalla C, Hetzer R, Transpl Immunol 2010 23 3 93 103 10.1016/j.trim.2010. 04.007 20434559
4. Cyclosporine A treated in vitro models induce cholestasis response through comparison of phenotype-directed gene expression analysis of in vivo Cyclosporine A-induced cholestasis. Kienhuis AS, Vitins AP, Pennings JL, Pronk TE, Speksnijder EN, Roodbergen M, van Delft JH, Luijten M, van der Ven LT, Toxicol Lett 2013 221 3 225 236 10.1016/j.toxlet.2013.06.236 23830897
5. Drug-induced cholestasis in the perfused rat liver and its reversal by tauroursodeoxycholate: an ultrastructural study. Abernathy CO, Zimmerman HJ, Ishak KG, Utili R, Gillespie J, Proc Soc Exp Biol Med 1992 199 1 54 58 10.3181/00379727-199-43328 1728037
6. Molecular basis of intrahepatic cholestasis. Carlton VE, Pawlikowska L, Bull LN, Ann Med 2004 36 8 606 617 10.1080/07853890410018916 15768832 (Pubitemid 40051437)
7. Identification of a new inborn error in bile acid synthesis: mutation of the oxysterol 7alpha-hydroxylase gene causes severe neonatal liver disease. Setchell KD, Schwarz M, O'Connell NC, Lund EG, Davis DL, Lathe R, Thompson HR, Weslie TR, Sokol RJ, Russell DW, J Clin Invest 1998 102 9 1690 1703 10.1172/JCI2962 9802883 (Pubitemid 28516254)
8. Diagnosis in bile acid-CoA: amino acid N-acyltransferase deficiency. Hadzic N, Bull LN, Clayton PT, Knisely AS, World J Gastroenterol 2012 18 25 3322 3326 22783059
9. Nuclear receptors as drug targets in cholestasis and drug-induced hepatotoxicity. Zollner G, Wagner M, Trauner M, Pharmacol Ther 2010 126 3 228 243 10.1016/j.pharmthera.2010.03.005 20388526
10. Bile acid transporters and regulatory nuclear receptors in the liver and beyond. Halilbasic E, Claudel T, Trauner M, J Hepatol 2013 58 1 155 68 10.1016/j.jhep.2012.08.002 22885388
11. Mitochondrial involvement in drug-induced hepatic injury. Kass GE, Chem Biol Interact 2006 163 1-2 145 159 16889760 (Pubitemid 44572218)
12. Mechanisms of disease: mechanisms and clinical implications of cholestasis in sepsis. Geier A, Fickert P, Trauner M, Nat Clin Pract Gastroenterol Hepatol 2006 3 10 574 585 10.1038/ncpgasthep0602 17008927 (Pubitemid 44489590)
13. The role of lithocholic acid in the regulation of bile acid detoxication, synthesis, and transport proteins in rat and human intestine and liver slices. Khan AA, Chow EC, Porte RJ, Pang KS, Groothuis GM, ToxicolIn Vitro 2011 25 1 80 90 10.1016/j.tiv.2010.09.011
14. Microarray analysis in rat liver slices correctly predicts in vivo hepatotoxicity. Elferink MG, Olinga P, Draaisma AL, Merema MT, Bauerschmidt S, Polman J, Schoonen WG, Groothuis GM, ToxicolApplPharmacol 2008 229 3 300 309
15. Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: a review. Silva MF, Aires CC, Luis PB, Ruiter JP, IJlst L, Duran M, Wanders RJ, Tavares de Almeida I, J Inherit Metab Dis 2008 31 2 205 216 10.1007/s10545-008-0841-x 18392741
16. Prescribing amiodarone: an evidence-based review of clinical indications. Vassallo P, Trohman RG, JAMA 2007 298 11 1312 1322 10.1001/jama.298.11.1312 17878423 (Pubitemid 47449439)
17. Liver necrosis and lipid peroxidation in the rat as the result of paraquat and diquat administration. Effect of selenium deficiency. Burk RF, Lawrence RA, Lane JM, J Clin Invest 1980 65 5 1024 1031 10.1172/JCI109754 7364936 (Pubitemid 10043597)
18. Isoniazid hepatoxicity: the relationship between covalent binding and metabolism in vivo. Timbrell JA, Mitchell JR, Snodgrass WR, Nelson SD, J Pharmacol Exp Ther 1980 213 2 364 369 6767840 (Pubitemid 10109641)
19. Reference histology of veal calf genital and endocrine tissues-an update for screening on hormonal growth promoters. Groot MJ, Ossenkoppele JS, Bakker R, Pfaffl MW, Meyer HH, Nielen MW, J Vet Med A Physiol Pathol Clin Med 2007 54 5 238 246 10.1111/j.1439-0442.2007.00927.x 17523956 (Pubitemid 46794214)
20. Different effects of the probe summarization algorithms PLIER and RMA on high-level analysis of Affymetrix exon arrays. Qu Y, He F, Chen Y, BMC Bioinformatics 2010 11 211 10.1186/1471-2105-11-211 20426803
21. Omics analysis of low dose acetaminophen intake demonstrates novel response pathways in humans. Jetten MJ, Gaj S, Ruiz-Aracama A, de Kok TM, van Delft JH, Lommen A, van Someren EP, Jennen DG, Claessen SM, Peijnenburg AA, et al. Toxicol Appl Pharmacol 2012 259 3 320 328 10.1016/j.taap.2012.01.009 22285215
22. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, et al. Proc Natl Acad Sci U S A 2005 102 43 15545 15550 10.1073/pnas.0506580102 16199517 (Pubitemid 41528093)
23. Anni 2.0: a multipurpose text-mining tool for the life sciences. Jelier R, Schuemie MJ, Veldhoven A, Dorssers LC, Jenster G, Kors JA, Genome Biol 2008 9 6 96 10.1186/gb-2008-9-6-r96 18549479 (Pubitemid 351993168)
24. STRING v9.1: protein-protein interaction networks, with increased coverage and integration. Franceschini A, Szklarczyk D, Frankild S, Kuhn M, Simonovic M, Roth A, Lin J, Minguez P, Bork P, von Mering C, et al. Nucleic Acids Res 2013 41 Database issue 808-815 23203871
25. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Livak KJ, Schmittgen TD, Methods 2001 25 4 402 408 10.1006/meth.2001.1262 11846609 (Pubitemid 34164012)
26. Proteomics investigations of drug-induced hepatotoxicity in HepG2 cells. van Summeren A, Renes J, Bouwman FG, Noben JP, van Delft JH, Kleinjans JC, Mariman EC, Toxicol Sci 2011 120 1 109 122 10.1093/toxsci/kfq380 21163907
27. Regulation of gluconeogenesis by Kruppel-like factor 15. Gray S, Wang B, Orihuela Y, Hong EG, Fisch S, Haldar S, Cline GW, Kim JK, Peroni OD, Kahn BB, et al. Cell Metab 2007 5 4 305 312 10.1016/j.cmet.2007.03.002 17403374 (Pubitemid 46477856)
28. Glucocorticoid receptor mediates the gluconeogenic activity of the farnesoid X receptor in the fasting condition. Renga B, Mencarelli A, D'Amore C, Cipriani S, Baldelli F, Zampella A, Distrutti E, Fiorucci S, FASEB J 2012 26 7 3021 3031 10.1096/fj.11-195701 22447981
29. Bile acids as regulators of hepatic lipid and glucose metabolism. Trauner M, Claudel T, Fickert P, Moustafa T, Wagner M, J Dig Dis 2010 28 1 220 224 10.1159/000282091
30. Influence of Verapamil and Cyclosporin A on bile acid metabolism and transport in rat liver slices. Barth A, Braun J, Muller D, Exp Toxicol Pathol 2006 58 1 31 37 10.1016/j.etp.2006.04.003 16793245 (Pubitemid 44093215)
31. Effects of chlorpromazine on Na + -K + -ATPase pumping and solute transport in rat hepatocytes. Van Dyke RW, Scharschmidt BF, Am J Physiol 1987 253 5 Pt 1 613 G621 2446505
32. AMAP, the alleged non-toxic isomer of acetaminophen, is toxic in rat and human liver. Hadi M, Dragovic S, van Swelm R, Herpers B, van de Water B, Russel FG, Commandeur JN, Groothuis GM, Arch Toxicol 2013 87 1 155 165 10.1007/s00204-012-0924-1 22914986
33. Interspecies differences in acetaminophen sensitivity of human, rat, and mouse primary hepatocytes. Jemnitz K, Veres Z, Monostory K, Kobori L, Vereczkey L, Toxicol In Vitro 2008 22 4 961 967 10.1016/j.tiv.2008.02.001 18346862
34. Prevention by dietary (n-6) polyunsaturated phosphatidylcholines of intrahepatic cholestasis induced by cyclosporine A in animals. Chanussot F, Benkoel L, Life Sci 2003 73 4 381 392 10.1016/S0024-3205(03)00292-3 12759133 (Pubitemid 36577564)
35. Oxidative stress plays a major role in chlorpromazine-induced cholestasis in human HepaRG cells. Antherieu S, Bachour-El Azzi P, Dumont J, Abdel-Razzak Z, Guguen-Guillouzo C, Fromenty B, Robin MA, Guillouzo A, Hepatology 2013 57 4 1518 1529 10.1002/hep.26160 23175273
36. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Sinal CJ, Tohkin M, Miyata M, Ward JM, Lambert G, Gonzalez FJ, Cell 2000 102 6 731 744 10.1016/S0092-8674(00)00062-3 11030617
37. In vitro assay for drug-induced hepatosteatosis using rat primary hepatocytes, a fluorescent lipid analog and gene expression analysis. Fujimura H, Murakami N, Kurabe M, Toriumi W, J Appl Toxicol 2009 29 4 356 363 10.1002/jat.1420 19224547
38. Effect of cyclosporine A on hepatic carbohydrate metabolism and hepatic gene expression in rat. Delgado TC, Barosa C, Nunes PM, Scott DK, O'Doherty RM, Cerdan S, Geraldes CF, Jones JG, Expert Opin Drug Metab Toxicol 2012 8 10 1223 1230 10.1517/17425255.2012.709500 22870958
39. Effect of thioridazine or chlorpromazine on increased hepatic NAD + level in rats fed clofibrate, a hypolipidaemic drug. Shin M, Asada S, Mizumori N, Sano K, Umezawa C, J Pharm Pharmacol 1998 50 4 431 436 10.1111/j.2042-7158.1998. tb06884.x 9625489 (Pubitemid 28197422)
40. Difference between effects of chlorpromazine and perphenazine on microsomal phospholipids and enzyme activities in rat liver. Hoshi K, Fujino S, J Toxicol Sci 1992 17 2 69 79 10.2131/jts.17.69
41. An orally available small imidazolium salt ameliorates inflammation and fibrosis in a murine model of cholestasis. Ding Z, Kng Y, Yang H, Ke Z, Zhuo L, Lab Invest 2011 91 5 752 763 10.1038/labinvest.2011.11 21339743
42. Exploring cyclosporine A-side effects and the protective role-played by antioxidants: the morphological and immunohistochemical studies. Rezzani R, Histol Histopathol 2006 21 3 301 316 16372251 (Pubitemid 43033739)
43. Cyclosporine A-induced oxidative stress in rat hepatocytes. Wolf A, Trendelenburg CF, ez-Fernandez C, Prieto P, Houy S, Trommer WE, Cordier A, J Pharmacol Exp Ther 1997 280 3 1328 1334 9067320 (Pubitemid 27166730)
44. Control of NF-kappaB and inflammation by the unfolded protein response. Kitamura M, Int Rev Immunol 2011 30 1 4 15 10.3109/08830185.2010.522281 21235322
45. The role of chemokines in the recruitment of lymphocytes to the liver. Oo YH, Shetty S, Adams DH, Dig Dis 2010 28 1 31 44 10.1159/000282062 20460888
46. Recruitment and interaction of human dendritic and T cells in autologous liver slices experimentally infected with HCV produced in cell culture. Nascimbeni M, Bourdoncle P, Penna C, Saunier B, J Immunol Methods 2012 378 1-2 51 55 22349126
47. Heat shock proteins: facts, thoughts, and dreams. De Maio A, Shock 1999 11 1 1 12 10.1097/00024382-199901000-00001
48. The translocon: a dynamic gateway at the ER membrane. Johnson AE, van Waes MA, Annu Rev Cell Dev Biol 1999 15 799 842 10.1146/annurev.cellbio.15.1.799 10611978 (Pubitemid 32250392)
49. Cyclosporine-relationship of side effects to mode of action. Ryffel B, Foxwell BM, Gee A, Greiner B, Woerly G, Mihatsch MJ, Transplantation 1988 46 2 Suppl 90S 96S 3043800
50. Inhibition of hepatocytary vesicular transport by cyclosporin A in the rat: relationship with cholestasis and hyperbilirubinemia. Roman ID, Monte MJ, Gonzalez-Buitrago JM, Esteller A, Jimenez R, Hepatology 1990 12 1 83 91 10.1002/hep.1840120114 2373489 (Pubitemid 20234012)
51. Intravenous bilirubin infusion causes vacuolization of the cytoplasm of hepatocytes and canalicular cholestasis. Veel T, Villanger O, Holthe MR, Skjorten FS, Raeder MG, Acta Physiol Scand 1991 143 4 421 429 10.1111/j.1748-1716.1991.tb09254.x 1815476
52. Repression of farnesoid X receptor during the acute phase response. Kim MS, Shigenaga J, Moser A, Feingold K, Grunfeld C, J Biol Chem 2003 278 11 8988 8995 10.1074/jbc.M212633200 12519762 (Pubitemid 36800376)
53. Tumor necrosis factor and interleukin 1 decrease RXRalpha, PPARalpha, PPARgamma, LXRalpha, and the coactivators SRC-1, PGC-1alpha, and PGC-1beta in liver cells. Kim MS, Sweeney TR, Shigenaga JK, Chui LG, Moser A, Grunfeld C, Feingold KR, Metabolism 2007 56 2 267 279 10.1016/j.metabol.2006.10.007 17224343 (Pubitemid 46084934)
54. Multiparametric immunotoxicity screening in mice during early drug development. Auli M, Domenech A, Andres A, Orta M, Salva M, Descotes J, Prats N, Toxicol Lett 2012 214 2 200 208 10.1016/j.toxlet.2012.08.020 22944472
55. Treatment of Nonalcoholic Fatty Liver Disease. Liangpunsakul S, Chalasani N, Curr Treat Options Gastroenterol 2003 6 6 455 463 10.1007/s11938-003-0047-0 14585234
56. Alcoholic liver disease. Yip WW, Burt AD, Semin Diagn Pathol 2006 23 3-4 149 160 17355088 (Pubitemid 46176510)
57. Microvascular remodeling and wound healing: a role for pericytes. Dulmovits BM, Herman IM, Int J Biochem Cell Biol 2012 44 11 1800 1812 10.1016/j.biocel.2012.06.031 22750474
58. Burden of liver disease in the United States: summary of a workshop. Kim WR, Brown RS Jr, Terrault NA, El-Serag H, Hepatology 2002 36 1 227 242 10.1053/jhep.2002.34734 12085369 (Pubitemid 34700782)